Antares Pharma — Investor Presentation (March 2022)
25 slides from Antares Pharma's investor presentation, Mar 7, 2022
Slide 1: March 2022 Investor Presentation
NASDAQ: ATRS | March 2022 Investor Presentation Exhibit 99.1
Slide 2: Safe Harbor Statement & Non-GAAP Metrics
2March 2022 Safe Harbor Statement & Non-GAAP Metrics This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward- looking statements are subject to certain risks and uncertainties that can cau
Slide 3: Investment Highlights
3March 2022 Leverage pharmaceutical and medical device expertise to develop innovative products that address needs in underserved therapeutic areas Investment Highlights Diversified revenue provides opportunities for continued growth Commercial XYOSTED® and NOCDURNA® Commercial Generic EpiPen®, Gene
Slide 4: Long-Term Growth Strategy
4March 2022 Long-Term Growth Strategy Expand Partnership Opportunities A leader in self-administered injection technology Support life-cycle management solutions Disciplined Capital Allocation Corporate development In-licensing opportunities Enhance Proprietary Portfolio Support research and develop
Slide 5: Rapidly Growing and Diversified Revenue Mix
5March 2022 42% 34% 10% 14% FY 2020 32% 42% 6% 20% FY 2019 28% 47% 11% 14% FY 2018 Rapidly Growing and Diversified Revenue Mix Proprietary Products Partner Products Development Royalty Revenue $63.6M Revenue $123.9M Revenue $149.6M 43% 25% 11% 21% FY 2021 Revenue $184.0M
Slide 6: Proprietary Products
Proprietary Products (desmopressin acetate) sublingual tablet
Slide 7: Patient-Centric Innovation Drives Strategy
7March 2022 Patient-Centric Innovation Drives Strategy Targeting two therapeutic areas with significant market opportunities UROLOGY & ENDOCRINOLOGY Focus on patient populations with unmet needs Target addressable physician audiences for efficient commercialization Identify and develop innovative, d
Slide 8: XYOSTED and TLANDO
8 Innovative self-delivery of testosterone (T) replacement therapy for at-home use • T levels maintained for as long as the patient remains on therapy* • Convenient, once-a-week dosing • Virtually painless subcutaneous injection ~75% of all commercial lives covered 18 Orange Book listed patents exte
Slide 9: Testosterone Market
9March 2022 Testosterone Market Once Weekly Painless Efficacious Steady PK No Risk of Transfer 0 500,000 1,000,000 1,500,000 2,000,000 2,500,000 3,000,000 3,500,000 4,000,000 4,500,000 2021 TRT Growth: 5.1% 2021 TRT INJECTABLE Growth: 5.4% 2021 TRT Topical Growth: 0% 2021 TRT TRx: 8.0M 2021 TRT Inje
Slide 10: XYOSTED Quarterly TRx Growth
10March 2022 XYOSTED® Quarterly TRx Growth Written by ~11,000 different physicians (since launch) 4Q 2021 TRx’s increased ~34% year-over-year 4Q 2021 TRx’s increased ~8% sequentially 3,207 6,485 10,290 14,064 16,777 17,685 21,461 23,274 24,493 27,961 29,795 32,677 796 4,517 8,893 13,638 16,387 20,58
Slide 11: Focused Sales Effort to Optimize Current Portfolio
11March 2022 • Branded TRT/IM and Desmopressin/OAB/BPH • ~95% of TRT prescribers in the top 3 deciles is covered • ~50%+ of NOCDURNA® targets are also XYOSTED® targets • Every territory is covering 60 ATRS brand prescriber and 60- 90 targeted prescriber Recently expanded sales team • 122 FTE: 108 SA
Slide 12: NOCDURNA (desmopressin acetate)
12March 2022 FDA-approved vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times a night to void • First and only sublingual tablet that targets the kidneys • Short-acting desmopressin is underutilized due to poor disease state an
Slide 13: NOCDURNA Works Quickly
13March 2022 NOCDURNA® Works Quickly A sublingual tablet that dissolves rapidly1 Administered without water1 Onset action occurs within 30 minutes1 Therapeutic effect as early as the first night1 Elimination from the body starts quickly, within a half-life of 2.8 hours1 Antidiuretic effect lasts 6 h
Slide 14: Antares Assets in Development
14March 2022 ATRS-1901 Urology Asset Antares Assets in Development ATRS-1902 for Adrenal Crisis Rescue Completed Pre-IND meeting with FDA Filed IND with FDA in June 2021 Reported positive Phase I study results Expect to conduct clinical PK and human factor study in 2022 Target to file 505(b)(2) NDA
Slide 15: ATRS-1902 for Adrenal Crisis Rescue
15March 2022 ATRS-1902 for Adrenal Crisis Rescue + 62% 6% 6% 12% 14% ENDOCRINOLOGY PEDIATRICS NURSE PRACTITIONER PRIMARY CARE ALL OTHERS Solu-Cortef® Prescribers(4) Simple (2-step), integrated device versus standard-of-care, Solu-Cortef® sterile powder that requires reconstitution and multiple steps
Slide 16: Partner Business
16March 2022 Deep Device Knowledge Partner Business: Extensive Regulatory Expertise and Success Tailored Durable Asset Development PHARMACEUTICAL TECHNOLOGY PARTNER $0.0 $20.0 $40.0 $60.0 $80.0 $100.0 $120.0 2015 2016 2017 2018 2019 2020 2021 Partner Product License and Development Royalties $32.4 $
Slide 17: Teva's Generic EpiPen
17March 2022 Commercial Experience Teva’s Generic EpiPen FDA-approved as therapeutically equivalent to Mylan’s EpiPen® and fully substitutable at the pharmacy Antares receives cost plus margin on all devices sold to Teva plus mid-to-high, single-digit royalties on net sales Teva garnered ~56%* share
Slide 18: Generic EpiPen Quarterly TRx Prescription Trends
18March 2022 Generic EpiPen® Quarterly TRx Prescription Trends Bloomberg/Symphony Health Solutions 28,750 / 6% 125,000 / 22% 237,000 / 27% 183,000 / 36% 206,000 / 43% 176,000 / 38% 293,000 / 43% 232,000 / 48% 305,000 / 53% 445,000 / 58% 561,000 / 58% 448,750 568,000 862,000 506,000 484,000 465,000 6
Slide 19: Generic Forteo (teriparatide)
19March 2022 Teva launched ROW 12 European countries Israel and Canada Forteo® 2021 revenue $441.6 million in U.S. by Lilly $360.3 million in ROW by Lilly Attractive economics to ATRS Supply devices at reasonable margin Royalties escalating to mid-teens Potential FDA approval Expect fully substituta
Slide 20: Global Development Agreement with Idorsia for selatogrel
20March 2022 Global Development Agreement with Idorsia Pharmaceuticals for selatogrel, a New Chemical Entity, with the QuickShot® auto injector selatogrel Selatogrel is a potent and highly selective P2Y12 receptor antagonist intended for the treatment of suspected Acute Myocardial Infarction (AMI) P
Slide 21: Myocardial Infarction Market Opportunity
21March 2022 • ~800,000 occurrences of new or recurrent MI1 annually • 600,000 have a first MI + 200,000 have a recurrent MI Myocardial Infarction Market Opportunity 1. Mozaffarian D et al. Circulation 2016 * American Heart Association ~8.4 million Americans* have survived a Myocardial Infarction (M
Slide 22: Diversified Product Portfolio
22March 2022 Diversified Product Portfolio Testosterone Desmopressin Acetate Sumatriptan Epinephrine Hydroxyprogesterone Teriparatide Testosterone Teriparatide P2Y12 Receptor Antagonist Undisclosed Hydrocortisone Undisclosed Undisclosed XYOSTED® NOCDURNA® SUMATRIPTAN EPINEPHRINE MAKENA® TERIPARATIDE
Slide 23: Revenue Growth and 2022 Projections
50% 51% 59% 58% 63% 0% 10% 20% 30% 40% 50% 60% 70% 80% 2017 2018 2019 2020 2021 Gross Margin $54.5M $63.6M $123.9M $149.6M $184.0M $200-220M* 2017 2018 2019 2020 2021 2022 +4% vs. 2016 +21% vs. 2019 +17% vs. 2017 +95% vs. 2018 Revenue Growth and 2022 Projections Projected 5-Year CAGR of ~31%*** * Re
Slide 24: 2022 Invest and Grow Strategy
24March 2022 2022 Invest and Grow Strategy Internal Pipeline Expansion Commercial Expansion of Organizational Structure and Capabilities Corporate Development New scalable structure to support future growth Efficient and scalable Leveraging resources to accelerate opportunities New candidates and ac
Slide 25: Antares Pharma: Long-Term Value Proposition
25March 2022 Antares Pharma: Long-Term Value Proposition Diverse portfolio of commercialized products Multiple growth drivers • Continued XYOSTED® prescription growth • Continued generic EpiPen® prescription growth • NOCDURNA® prescription growth • Pending FDA approval and commercial launch of TLAND